ASIC accuses ASX company of misleading COVID-19 claims

The chief executive of the WA business allegedly said on a YouTube video that its sanitiser spray can kill the coronavirus, but this had not been tested.

| More on:
asx share penalty represented by lots of fingers pointing at disgraced businessman Crown royal commission WA

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

An ASX-listed company, together with its chief executive, has been accused of spruiking false COVID-killing claims about its products.

The Australian Securities and Investments Commission (ASIC) is suing Holista Colltech Limited (ASX: HCT) and its executive chair Dr Rajendran Marnickavasagar, seeking penalties and declarations from the Federal Court.

The corporate watchdog is also advocating for Marnickavasagar to be banned from managing corporations.

Holista shares are currently in a trading halt, pending a response from the Western Australian company.

The stock last traded for 6.6 cents, giving Holista a market capitalisation of around $18 million.

The accusations against Holista

Marnickavasagar allegedly stated in a YouTube video in February 2020 that Holista's NatShield sanitiser spray killed the coronavirus "involved in the current Wuhan outbreak".

ASIC is claiming this was misleading as the product had not been tested against COVID-19 at the time.

Holista also announced to the ASX on 9 April 2020 that 415,000 bottles of NatShield were purchased by a business named Health Therapies. 

ASIC alleges this $3.8 million order had not been placed at the time.

The ASX company then disclosed to the market on 9 July 2020 that the Health Therapies deal would not be met, and its total revenue for the financial year was back down to just $500,000.

In another ASX announcement in February 2020, Holista claimed it had executed a binding term sheet with another business to collaborate on a new sanitising nasal balm product.

This disclosure is also alleged to be false, as ASIC claims the deal was actually executed 2 months later.

ASIC deputy chair Sarah Court said her organisation is continuing to focus on misleading claims about COVID-19.

"In this case, we are concerned by the allegedly misleading claims, made when there were concerns about a potential pandemic, that NatShield was effective against the virus later known as COVID-19 when it had not been tested against that virus."

The corporate regulator is accusing Holista of violations of the Corporations Act in its civil proceedings.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »